Collaboration With Merck’s Protease Inhibitor The Fourth HCV Tie-Up For Bristol’s Daclatasvir
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck and Bristol will run a Phase II trial testing daclatasvir, an NS5A replication complex inhibitor, in tandem with MK-5172, Merck’s potentially pan-genotypic protease inhibitor in a non-exclusive partnership in hepatitis C. It’s the second such deal Bristol has signed this month, following an April 5 agreement with Vertex.
You may also be interested in...
Asunaprevir NDA Withdrawal Likely To Mean Daclatasvir Delay
Bristol pulls NDA for its second-generation protease inhibitor, which likely will alter the data needed for approval of its simultaneously filed NS5A inhibitor. Recent approval of daclatasvir in Europe may offer a glimpse at Bristol’s revised U.S. strategy in HCV.
Asunaprevir NDA Withdrawal Likely To Mean Daclatasvir Delay
Bristol pulls NDA for its second-generation protease inhibitor, which likely will alter the data needed for approval of its simultaneously filed NS5A inhibitor. Recent approval of daclatasvir in Europe may offer a glimpse at Bristol’s revised U.S. strategy in HCV.
Bristol Halts HCV Trial Of Inhibitex Nuc Due To Possible Cardiac Toxicity
Bristol had paid $2.5 billion to buy Inhibitex and its Phase II nucleoside polymerase inhibitor in hopes of keeping pace with Gilead in the race to develop the first all-oral combination of direct-acting antivirals for hepatitis C.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: